HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.

Abstract
Several lines of evidence suggest that the nicotinic acetylcholine receptor alpha7 (nAChR alpha7) is involved in central nervous system disorders like schizophrenia and Alzheimer's disease as well as in inflammatory disorders like sepsis and pancreatitis. The present article describes the in vivo effects of JN403, a compound recently characterized to be a potent and selective partial nAChR alpha7 agonist. JN403 rapidly penetrates into the brain after i.v. and after p.o. administration in mice and rats. In the social recognition test in mice JN403 facilitates learning/memory performance over a broad dose range. JN403 shows anxiolytic-like properties in the social exploration model in rats and the effects are retained after a 6h pre-treatment period and after subchronic administration. The effect on sensory inhibition was investigated in DBA/2 mice, a strain with reduced sensory inhibition under standard experimental conditions. Systemic administration of JN403 restores sensory gating in DBA/2 mice, both in anaesthetized and awake animals. Furthermore, JN403 shows anticonvulsant potential in the audiogenic seizure paradigm in DBA/2 mice. In the two models of permanent pain tested, JN403 produces a significant reversal of mechanical hyperalgesia. The onset was fast and the duration lasted for about 6h. Altogether, the present set of data suggests that nAChR alpha7 agonists, like JN403 may be beneficial for improving learning/memory performance, restoring sensory gating deficits, and alleviating pain, epileptic seizures and conditions of anxiety.
AuthorsDominik Feuerbach, Kurt Lingenhoehl, Hans-Rudolf Olpe, Annick Vassout, Conrad Gentsch, Frederique Chaperon, Joachim Nozulak, Albert Enz, Graeme Bilbe, Kevin McAllister, Daniel Hoyer
JournalNeuropharmacology (Neuropharmacology) Vol. 56 Issue 1 Pg. 254-63 (Jan 2009) ISSN: 0028-3908 [Print] England
PMID18793655 (Publication Type: Journal Article)
Chemical References
  • (S)-(1-azabicyclo(2.2.2)oct-3-yl)carbamic acid (S)-1-(2-fluorophenyl) ethyl ester
  • Carbamates
  • Chrna7 protein, mouse
  • Chrna7 protein, rat
  • Nicotinic Agonists
  • Quinuclidines
  • Receptors, Nicotinic
  • alpha7 Nicotinic Acetylcholine Receptor
  • Nicotine
Topics
  • Acoustic Stimulation (adverse effects, methods)
  • Analysis of Variance
  • Animals
  • Carbamates (metabolism, pharmacology, therapeutic use)
  • Cognition (drug effects)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Routes
  • Epilepsy (drug therapy, etiology)
  • Evoked Potentials, Auditory (drug effects)
  • Exploratory Behavior (drug effects)
  • Hippocampus (drug effects)
  • Male
  • Mice
  • Mice, Inbred DBA
  • Nicotine (pharmacology)
  • Nicotinic Agonists (metabolism, pharmacology, therapeutic use)
  • Pain (drug therapy)
  • Pain Threshold (drug effects)
  • Quinuclidines (metabolism, pharmacology, therapeutic use)
  • Rats
  • Receptors, Nicotinic (physiology)
  • Sensory Gating (drug effects)
  • Social Behavior
  • Time Factors
  • alpha7 Nicotinic Acetylcholine Receptor

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: